Solasia Pharma K.K. (FRA:9SO)
Germany · Delayed Price · Currency is EUR 0.1630
+0.0110 (7.24%)
Last updated: Nov 28, 2025, 9:35 PM CET
Solasia Pharma K.K. Company Description
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries.
The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma.
It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-05 for the treatment of colorectal cancer.
The company was founded in 2006 and is based in Tokyo, Japan.
Solasia Pharma K.K.
| Country | Japan |
| Founded | 2006 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 23 |
| CEO | Yoshihiro Arai |
Contact Details
Address: Sumitomo Fudosan Shiba-Koen Tower Tokyo, 105-0011 Japan | |
| Phone | 81 3 5843 8045 |
| Website | solasia.co.jp |
Stock Details
| Ticker Symbol | 9SO |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yoshihiro Arai | Chief Executive Officer |
| Toshio Miyashita | Chief Financial Officer |